Vinorelbine thiotepa in metastatic breast cancer: a large real-life retrospective study

Click to increase image sizeClick to decrease image size

Ethics statement

All alive patients received written information and provided their oral consent for data collection. Patients’ clinical charts were retrospectively collected from electronic files using a de-identified form. This study was approved by the Ethical Review Board of the French College of Gynecologists and Obstetricians (2022-GYN-0304). In accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines, we have structured the reporting of our study to ensure comprehensive and transparent presentation of our research methodology and findings (STROBE checklist: cohort studies, Supplementary Table S1).

Author contributions

Rebecca Loison: conceptualization, data curation, formal analysis, investigation, methodology, resources, visualization, writing original draft, and writing review and editing. Baptiste Abbar: formal analysis, data curation, methodology, visualization, and writing review and editing. Leonor Drouin, Charlotte Bonnet-Bensimon, Caroline Cuvier, Sylvie Giacchetti, and Marc Espie: resources and writing review and editing. Luis Teixeira: conceptualization, investigation, methodology, project administration, resources, supervision, validation, visualization, and writing review and editing. Victoire De Castelbajac: conceptualization, investigation, methodology, project administration, resources, supervision, validation, visualization, and writing review and editing.

Disclosure statement

BA has received consultant or advisory role fees or meeting invitations from Novartis, Astellas, Sanofi, AstraZeneca, Janssen, MSD, Pfizer, IPSEN Pharma, and Takeda. SG has received consultant or advisory role fees or travel accommodations from Novartis, EISAI, MSD, and Viatris. LT has received consultant or advisory role fees or travel accommodations or research grants from AZD, Daiichi, Gilead, MSD, Novartis, Pfizer, Roche, Pfizer, and Mylan. RL, LD, CBB, CC, and VDC have declared no conflict of interest. All authors have declared no conflicts of interest directly related to this study.

Data availability statement

The data that support the findings of this study are available from the corresponding author, BA, upon reasonable request.

Additional information

Funding

None.